Highlights
- 4DMedical (ASX:4DX) reported AUD 7.1 million in FY26 operating revenue.
- Annual scan volumes reached 344,075, increasing 77% year on year.
- SimonMed announced a commercial CT:VQ and LDAf rollout in November.
- The company held AUD 278 million cash at June 2026.
4DMedical Limited develops software that measures lung structure and function from medical imaging, including its CT:VQ ventilation-perfusion analysis technology. On November 16, 2026, 4DMedical (ASX:4DX) traded at AUD 2.27, down 1.30% during the session. Its recent developments include a November clinical launch with SimonMed Imaging and a full-year report outlining increasing scan volumes and distribution arrangements.
Lung Imaging Software and Commercial Model
4DMedical (ASX:4DX) supplies quantitative respiratory imaging technology to healthcare providers. CT:VQ uses non-contrast CT scans to generate regional ventilation and perfusion information, while other products analyse lung density, ventilation and structural features. The company markets software tools that can be integrated with established medical imaging workflows, meaning adoption depends on hospital systems, imaging operators and clinical users.
The portfolio also includes XV LVAS, which evaluates lung ventilation using X-ray images, and other CT-based analysis products. The Business has commercial exposure to Australia and the United States, with additional authorised markets for CT:VQ. Regulatory clearance in one market should not be confused with reimbursement decisions or customer uptake in every other market.
November SimonMed Launch and US Expansion
4DMedical (ASX:4DX) announced on November 2, 2026, that SimonMed had launched CT:VQ and LDAf services, enabling physicians to order these analyses across its US imaging operations. The launch followed a three-year agreement with SimonMed, which the FY26 results described as operating more than 170 imaging centres across 10 states. The arrangement was established on commercial terms rather than a preliminary evaluation phase.
The company also identified commercial adoption at Stanford University, Cleveland Clinic, UC San Diego Health, the University of Miami and the University of Chicago Medicine as of June 2026. It reported an expanded North American distribution arrangement with Philips and various Australian imaging contracts after local approval for CT:VQ. Each arrangement has different utilisation, implementation and payment characteristics, so the existence of an agreement does not establish a particular realised revenue amount.
FY26 Financial and Operating Performance
4DMedical (ASX:4DX) reported AUD 7.1 million in Operating Revenue for FY26, up 21% year on year. Its software was being delivered across 540 sites globally at June 30, 2026, representing 39% growth over the preceding year. It processed 344,075 scans during FY26, up 77%, including 105,970 scans in the June quarter. These volumes include the established portfolio and should not all be attributed to the newer CT:VQ product.
The company held AUD 278 million in cash at June 30, 2026. It also reported a contracted German lung-screening deployment through contextflow covering approximately 25,000 procedures at 25 sites over three years. The Acquisition of contextflow added a European software and regulatory footprint. These developments expand the range of services and geographic markets, but revenue realisation depends on implementation and ongoing use.
US reimbursement for CT:VQ was confirmed at USD 650.50 per scan in the relevant setting, according to the company’s FY26 disclosure. This reimbursement figure should not be treated as the revenue retained by 4DMedical for each scan because the amount payable to a software supplier depends on commercial contracts and the relevant provider billing arrangements.
Risks and Monitoring Points
Commercialisation depends on clinical adoption, integration into radiology systems, customer onboarding and reimbursement rules. Competition from existing imaging pathways, evidence requirements and regulatory changes could influence deployment. Research and product development spending also continues as the company seeks to translate contracts and regulatory clearances into reported sales.
What to Watch Next
For 4DMedical (ASX:4DX), future reports can show utilisation of SimonMed’s network, scan Volume trends, revenue from the software portfolio and the contribution from European activities. The company has also launched its CLEAR clinical evidence programme for acute pulmonary embolism assessment. Such studies may inform future clinical positioning, but publication and regulatory outcomes cannot be presumed.
Key Insights
4DMedical has expanded CT:VQ distribution while reporting higher FY26 scan volumes and operating revenue. Its cash balance provides a measure of financial resources, but future results will need to demonstrate the commercial conversion of deployed products into recurring income. Customer use and clinical evidence remain important monitoring points.
_11_16_2026_11_23_16_765087.jpg)





Please wait processing your request...